What is Zongertinib used for?

28 June 2024

Avenue Therapeutics Inc., a specialty pharmaceutical company dedicated to developing and commercializing treatments for neurologic diseases, has announced the full enrollment of patients in its Phase 1b/2a clinical trial of AJ201. This trial aims to treat spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's Disease. AJ201 is the lead drug candidate for SBMA in Avenue's development pipeline, with topline results expected in the second quarter of 2024.

The trial is a 12-week, multicenter, randomized, double-blind study that includes 25 patients who have either been assigned to receive AJ201 (600 mg/day) or a placebo. The primary goal of this study is to evaluate the safety and tolerability of AJ201 in individuals with clinically and genetically confirmed SBMA. Given the slow progression of SBMA, it is challenging to demonstrate clinical efficacy in such a short period. However, secondary endpoints focusing on various biomarkers have been established to support proof of target engagement, which could indicate potential clinical success. These biomarkers include changes in mutant androgen receptor protein levels in skeletal muscle and alterations in fat and muscle composition as observed through MRI scans.

Researching Enrollment Complete in AJ201 Trial for Kennedy's Disease beyond the basics?

Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore Enrollment Complete in AJ201 Trial for Kennedy's Disease with Hiro LS Researcher →

Synapse Hiro LS Researcher AI-powered pharmaceutical intelligence

Spinal and bulbar muscular atrophy is a rare genetic neuromuscular disorder primarily affecting men. This X-linked condition arises from an expansion of the trinucleotide CAG repeat in the androgen receptor (AR), resulting in the formation of a mutant polyglutamine (polyQ) AR protein. This mutant protein aggregates and causes muscular atrophy, particularly in the limbs and bulbar regions. The weakening of bulbar muscles impacts chewing, speech, and swallowing, often leading to choking or aspiration, which can cause respiratory infections. Limb muscle involvement results in difficulties with walking and a higher risk of falls. Estimates of SBMA prevalence suggest it affects approximately 1 in 6,887 males. Currently, there are no FDA or EMA-approved treatments for SBMA.

AJ201 is a first-of-its-kind treatment aiming to modify SBMA by targeting multiple mechanisms, including the degradation of the abnormal androgen receptor protein and activation of the Nrf1 and Nrf2 pathways, which protect cells from oxidative stress-induced death. A successful Phase 1 study in 72 healthy volunteers demonstrated the safety and pharmacokinetic profile of AJ201. It is now under evaluation in a multicenter, randomized, double-blind Phase 1/2a clinical trial across six U.S. sites, focusing on its safety, pharmacokinetics, pharmacodynamics, and clinical response in SBMA patients. AJ201 has received Orphan Drug Designation from the FDA for SBMA, Huntington’s disease, and spinocerebellar ataxia. Avenue has an exclusive license agreement for AJ201 from AnnJi Pharmaceuticals covering the United States, Canada, European Union, Great Britain, and Israel.

Polyglutamine diseases, including SBMA, involve neurodegenerative conditions caused by expanded CAG repeats that encode long polyQ tracts in the affected proteins. There are currently nine recognized polyQ disorders. The aggregation of mutant proteins in affected tissues is a key pathological feature, with neuroinflammation, oxidative stress, and disrupted protein quality control being major contributing factors. AJ201 aims to mitigate these effects by enhancing the degradation of mutant AR aggregates, inducing antioxidant and heat shock responses, and increasing proteasome expression, making it a promising candidate for treating SBMA and potentially other polyQ diseases.

Avenue Therapeutics specializes in therapies for neurologic diseases, with a current portfolio that includes AJ201 for SBMA, BAER-101 for CNS diseases, and IV tramadol for acute postoperative pain. Based in Miami, FL, and founded by Fortress Biotech, Inc., Avenue continues to focus on addressing unmet medical needs in neurology.

Continue your Enrollment Complete in AJ201 Trial for Kennedy's Disease research with Synapse Hiro LS Researcher

This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.

Ask a biopharma research question with Synapse Hiro LS Researcher

Questions to explore:

  • What approved and investigational uses have been reported for Enrollment Complete in AJ201 Trial for Kennedy's Disease?
  • What is the mechanism of action of Enrollment Complete in AJ201 Trial for Kennedy's Disease, and which targets or pathways are involved?
  • Which clinical trials are evaluating Enrollment Complete in AJ201 Trial for Kennedy's Disease, and what outcomes have been reported?
  • What patents, publications, and regulatory sources provide the latest evidence on Enrollment Complete in AJ201 Trial for Kennedy's Disease?

Ask Synapse Hiro LS Researcher →

AI may make mistakes. Check important info.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成